Wellgistics Health, Inc. — fact timeline

Wellgistics Health, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“ng Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Form 10-K”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires that a listed company’s stockholders’ equity be at least $2,500,000 (the “Minimum Stockholders’ Equity Requirement”). As reported in its Form 10-K, as of December 31, 2025, the Company had a stockholders’ equity of $(12,447,801). The Company has taken affirmat”

Wellgistics Health, Inc. issued warrants to purchase shares of the Company’s common stock of warrant to certain accredited investors for $7.50 per share.

“The PIPE Warrants are exercisable for shares of Common Stock at an exercise price of $7.50 per share”

Wellgistics Health, Inc. issued in the aggregate principal amount of $21,132,812.50 of convertible note to certain accredited investors for aggregate cash purchase price of $16,906,250.

“shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (the “PIPE Warrants”). The Notes are being issued for an aggregate cash purchase price of $16,906,250, reflecting a 20% original issue discount, before deducting placement agent fees and offering expenses. The closing of the offering occurred on May 27, 2026 (the “Closing”).”

Wellgistics Health, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $21,132,812.50 (effective 2026-05-27).

“On May 27, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers convertible promissory notes in the aggregate principal amount of $21,132,812.50”

Wellgistics Health, Inc. amended Amendment No. 1 to Note Purchase Agreement with Robert Forster valued at $1,500,000 (effective 2026-05-19).

“On May 19, 2026, Wellgistics Health, Inc. (the “Company”) entered into an Amendment No. 1 to Note Purchase Agreement (the “Amendment”) with Robert Forster (the “Investor”), which amended that certain Note Purchase Agreement, dated as of April 1, 2026, by and between the Company and the Investor.”

Wellgistics Health, Inc. entered into Fully Binding Letter of Intent with EOS Technology Holdings, Inc., Scilex Holding Company / Scilex Holdings, Inc., Datavault AI, Inc., HealthBridge Advisors, LLC, and Fortitude Advisors, LLC (effective 2026-05-20).

“On May 20, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Fully Binding Letter of Intent, dated May 20, 2026 (the “Term Sheet”), with EOS Technology Holdings, Inc. (“EOS”), Scilex Holding Company / Scilex Holdings, Inc. (“SCLX”), Datavault AI, Inc. (“Datavault”), HealthBridge Advisors, LLC (“HBA”), and Fortitude Advisors, LLC (“Fortitude”).”

Wellgistics Health, Inc.: Certificate of Amendment to effect a 1-for-50 reverse stock split of common stock (effective 2025-05-26).

“On May 20, 2025, the Company filed with the Secretary of State of the State of Delaware the Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.”

Gerald Commissiong was appointed as Interim Co-Chief Executive Officer at Wellgistics Health, Inc..

“On May 20, 2026, in connection with the Term Sheet described in Item 1.01 of this Current Report on Form 8-K, the Board of Directors of Wellgistics Health, Inc. (the “Company”) appointed Gerald Commissiong as Interim Co-Chief Executive Officer of the Company, effective immediately.”

Wellgistics Health, Inc. reported first quarter ended March 31, 2026 results: revenue $0.929 million, net income net operating loss of $7.742 million, EPS $0.07. Guidance initiated.

“revenue opportunities,”noted Mr. Patel. First Quarter 2026 Corporate Highlights ● Sequential quarter over quarter revenue growth: ○ Q4-2025: $0.486 million ○ Q1-2026: $0.929 million ○ Q2-2026: The Company expects revenue of $1.775 million (projected, $0.86M already recognized through May 18, 2026) ● Added quantum key encryption functionality to the”

Wellgistics Health, Inc. entered into Forbearance Agreement with Marco Capital, Inc. valued at approximately $1.77 million (effective 2026-05-01).

“On May 1, 2026, Wellgistics, LLC (“Wellgistics”), a wholly owned subsidiary of Wellgistics Health, Inc. (the “Company”), entered into an Acknowledgment of Indebtedness, Forbearance and Repayment Agreement (the “Forbearance Agreement”) with Marco Capital, Inc. (“MCI”).”

Wellgistics Health, Inc. amended Amended Settlement Agreement with Silverback Capital Corporation (effective 2026-02-09).

“On February 9, 2026, Wellgistics Health, Inc. (the “Company”) entered into an Amended Settlement Agreement (the “Amended Settlement Agreement”) with Silverback Capital Corporation, which amended that certain Settlement Agreement previously referenced in the Original Report (the “Original Settlement Agreement”).”

Wellgistics Health, Inc. entered into Collaboration Agreement with Kare Rx Hub, LLC, Kare Pharmtech, LLC, and Healthstar Technologies, LLC valued at $2,000,000 (effective 2026-04-13).

“On April 13, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Collaboration Agreement (the “Collaboration Agreement”) with Kare Rx Hub, LLC (“Kare Hub”), Kare Pharmtech, LLC (“Kare Pharmtech”), and Healthstar Technologies, LLC (“Healthstar”), pursuant to which the parties agreed to collaborate through a newly formed limited liability company structure.”

Wellgistics Health, Inc. entered into Collaboration Agreement with Kare Rx Hub, LLC, Kare Pharmtech, LLC, and Healthstar Technologies, LLC valued at $2,000,000 (effective 2026-04-13).

“On April 13, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Collaboration Agreement (the “Collaboration Agreement”) with Kare Rx Hub, LLC (“Kare Hub”), Kare Pharmtech, LLC (“Kare Pharmtech”), and Healthstar Technologies, LLC (“Healthstar”), pursuant to which the parties agreed to collaborate through a newly formed limited liability company structure.”

Wellgistics Health, Inc. terminated Settlement Agreement with Silverback Capital Inc. (effective 2026-04-03).

“On April 3, 2026, Wellgistics Health, Inc. (the “Company”) delivered written notice to Silverback Capital Inc. terminating that certain Settlement Agreement and Stipulation, dated January 28, 2026 (the “Settlement Agreement”), previously entered into between the Company and Silverback Capital Inc.”

Wellgistics Health, Inc. incurred senior notes of up to $1,250,000 in aggregate principal amount with certain investors at 0% maturing the twelve (12) month anniversary of the date of issuance of the Notes, or (b) the date of closing of the next issuance and sale of capital stock of the Company.

“the Company agreed to issue and sell to the Investors in a private offering up to $1,250,000 in aggregate principal amount (the “Aggregate Principal Amount”) of promissory notes (the “Notes”) (the “Offering”).”

Wellgistics Health, Inc. entered into Note Purchase Agreement with certain investors valued at up to $1,250,000 in aggregate principal amount (effective 2026-04-01).

“On April 1, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $1,250,000 in aggregate principal amount (the “Aggregate Principal Amount”) of promissory notes (the “Notes”) (the “Offering”).”

Wellgistics Health, Inc. entered into Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC (effective 2026-03-06).

“On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC”

Wellgistics Health, Inc. entered into Settlement Agreement and Stipulation with Silverback Capital Corporation valued at Settlement of aggregate principal amount of not less than $10,712,734.16 in liabilities via issuance (effective 2026-01-28).

“Previously, on January 28, 2026, the Company and SCC entered into a Settlement Agreement and Stipulation (the “Settlement Agreement”), pursuant to which SCC agreed to acquire and settle certain bona fide liabilities and obligations of the Company in an aggregate principal amount of not less than $10,712,734.16 (the “Claim Amount”) (the “Settlement”).”

Wellgistics Health, Inc. issued warrant to Placement Agent and its designees for 5% of aggregate gross proceeds.

“the Company issued common stock purchase warrants, in the form filed as Exhibit 10.2 to this Current Report on Form 8-K (the “PA Warrants”) to the Placement Agent and its designees to purchase a number of shares of Company common stock equal to 5% of the aggregate gross proceeds received by the Company with an exercise price equal to the closing price of the common stock on the last trading day before closing of the Offering.”

Wellgistics Health, Inc. issued convertible note to certain investors (the "Investors") for up to $8,125,000 in aggregate principal amount; aggregate purchase price of $6,500,000.

“On January 16, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $8,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of secured convertible promissory notes (the “Notes”) (the “Offering”).”

Wellgistics Health, Inc. incurred convertible notes of up to $8,125,000 in aggregate principal amount with certain investors at 0% except in the event of an event of default, in which case, the default intere maturing the six (6) month anniversary of the date of issuance of the Notes, or the date of closing of the next issuance and sale of capital stock of the Company.

“On January 16, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $8,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of secured convertible promissory notes (the “Notes”) (the “Offering”).”

Wellgistics Health, Inc. entered into Placement Agency Agreement with Dawson James Securities, Inc. (effective 2026-01-16).

“On January 16, 2026, in connection with the Offering, the Company entered into a placement agency agreement, a copy of which is filed as Exhibit 10.3 to this Current Report on Form 8-K (the “Placement Agency Agreement”) with Dawson James Securities, Inc. (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s placement agent in connection with the Offering.”

Wellgistics Health, Inc. entered into Note Purchase Agreement with certain investors valued at up to $8,125,000 in aggregate principal amount (effective 2026-01-16).

“On January 16, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $8,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of secured convertible promissory notes (the “Notes”) (the “Offering”).”

Wellgistics Health, Inc. issued up to $3,125,000 in aggregate principal amount of convertible promissory notes of convertible note to certain investors for aggregate purchase price of $2,500,000, reflecting a 20% original issue discount.

“amount (the “Aggregate Principal Amount”) of convertible promissory notes (the “Notes”) (the “Offering”). The aggregate purchase price payable by all Investors for the Notes is $2,500,000, reflecting a 20% original issue discount. All principal and interest on the outstanding principal will accrue and, unless converted earlier as set forth below, be due and”

Wellgistics Health, Inc. entered into Placement Agency Agreement with Dawson James Securities, Inc. (the “Placement Agent”) (effective 2026-01-05).

“On January 5, 2026, in connection with the Offering, the Company entered into a placement agency agreement, a copy of which is filed as Exhibit 10.3 to this Current Report on Form 8-K (the “Placement Agency Agreement”) with Dawson James Securities, Inc. (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s placement agent in connection with the Offering.”

Wellgistics Health, Inc. entered into Note Purchase Agreement with certain investors (the "Investors") valued at up to $3,125,000 in aggregate principal amount (effective 2026-01-05).

“On January 5, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $3,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of convertible promissory notes (the “Notes”) (the “Offering”).”

Wellgistics Health, Inc. incurred convertible notes of up to $3,125,000 in aggregate principal amount with certain investors at 0% except in the event of an event of default, in which case, the default intere maturing on (a) the six (6) month anniversary of the date of issuance of the Notes, or (b) the date of closing of the next issuance and sale of capital stock of the Comp.

“On January 5, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $3,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of convertible promissory notes (the “Notes”) (the “Offering”).”

Wellgistics Health, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 9, 2025, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until June 8, 2026 (the “Compliance Period”), to regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule by June 8, 2026, the Company may be eligible for an additional 180-day period to reg”

Wellgistics Health, Inc. entered into License Agreement with DataVault AI Inc. valued at Non-refundable license fee of $2,500,000; royalty fee of 13% on net profit; minimum annual royalty o (effective 2025-11-24).

“Item 1.01. Entry into a Material Definitive Agreement. On November 24, 2025, Wellgistics Health, Inc. (the “ Company ”), entered into a license agreement (the “ License Agreement ”) with DataVault AI Inc. (“ DataVault ”) pursuant to which DataVault shall license certain intellectual property to the Company which the Company intends to use for purposes of developing manufacturer-to-patient blockchain-enabled smart contracts designed to optimize the Company’s proprietary technology and physical infrastructure for the prescription drug industry (“ PharmacyChainTM ”). The term of the License Agreement shall last for the life of DataVault’s patents underlying the proprietary materials, unless earlier terminated by the parties. In exchange for the license, the Company shall pay DataVault a non-refundable license fee equal to Two Million Five Hundred Thousand Dollars ($2,500,000.00) to be paid by December 31, 2025. The Company will pay DataVault a royalty fee equal to thirteen percent (13%) o”

Wellgistics Health, Inc. entered into License Agreement with DataVault AI Inc. valued at $2,500,000.00 (effective 2025-11-24).

“On November 24, 2025, Wellgistics Health, Inc. (the “ Company ”), entered into a license agreement (the “ License Agreement ”) with DataVault AI Inc. (“ DataVault ”)”

Wellgistics Health, Inc. engaged Suri & Co., Chartered Accountants as its auditor.

“On November 17, 2025, the Audit Committee of the Board of Directors approved the re-engagement of Suri & Co., Chartered Accountants (“Suri”), as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.”

UHY LLP resigned as auditor of Wellgistics Health, Inc..

“ormal notice that the Company’s independent auditors, UHY LLP (“UHY”), had made the decision to resign as the Company’s independent accountants effective November 11, 2025. UHY indicated that they have elected to resign in light of certain information identified in the resignation of the former Chief Executive Officer of the Company, which had not yet been investigated.”

Wellgistics Health, Inc. engaged UHY LLP as its auditor.

“On July 7, 2025, the Company's Board of Directors approved the engagement of UHY LLP ("UHY") as the Company's new independent registered public accounting firm, effective as of July 7, 2025.”

Wellgistics Health, Inc. dismissed Suri & Co., Chartered Accountants as its auditor.

“On July 7, 2025, the Board of Directors of Wellgistics Health, Inc. (the "Company") approved the dismissal of Suri & Co., Chartered Accountants ("Suri"), the Company's independent registered public accounting firm.”

Vishnu Balu departed as Chief Financial Officer at Wellgistics Health, Inc..

“Mr. Balu’s decision to resign is not the result of any dispute or disagreement with the Company, the Company’s management or the Company’s Board of Directors on any matter relating to the Company’s operations, policies or practices.”

Mark DiSiena was appointed as Chief Financial Officer at Wellgistics Health, Inc..

“On April 22, 2025, the Board of Directors of Wellgistics Health, Inc. (the “Company”) appointed Mark DiSiena as Chief Financial Officer of the Company, effective as of April 22, 2025”

Wellgistics Health, Inc. incurred loan of principal amount of $6,000,000 at rate of 4.5%, compounding annually maturing third anniversary of the date such note is made.

“an unsecured promissory note made by the Company (the “Note”) in the principal amount of $6,000,000 bearing interest at the rate of 4.5%, compounding annually, and maturing on the third anniversary of the date such note is made.”

Michael L. Peterson was appointed as Director at Wellgistics Health, Inc..

“the Board appointed Michael L. Peterson to fill the vacancy created as a result of Mr. Sayed’s departure.”

Sajid Sayed resigned as Director at Wellgistics Health, Inc..

“Sajid Sayed informed the Company’s board of directors of his intent to resign as a director of the Company, effective immediately.”

Timothy Canning departed as Chief Executive Officer at Wellgistics Health, Inc..

“Mr. Norton will succeed Timothy Canning, who served as the Company’s Chief Executive Officer since January 18, 2024, and who is resigning from his position, effective as of the Effective Date.”

Brian Norton was appointed as Chief Executive Officer at Wellgistics Health, Inc..

“promoted Brian Norton to serve as the Company’s Chief Executive Officer effective as of February 28, 2025”